Medicine@Yale

The center will have an ambitious goal: to produce better diagnoses, treatments, and ultimately cures for these diseases. It will also work toward vaccine development.

Seventeen years after it began, in 2005, publication of Medicine@Yale is coming to an end with this issue.

In his new role, Winer is working to promote paradigm-changing dis- covery and to build an unparalleled clinical program that offers seamless, multidisciplinary care and clinical trials to all patients, eliminating dis- parities in access, care, and outcomes.

To have the juxtaposition of being at an institution with such a rich history, but one that can, and wants to, move forward is very special, she says.

Isaac Y. Kim, MD, PhD, MBA, was appointed chair of the Department of Urology at Yale School of Medicine (YSM) and chief of Urology at Yale New Haven Hospital.

Made the cancer hospital that bears his name possible with a generous gift in 2007

In a clinical trial led by Kevan Herold, MD, teplizumab prevented or delayed clinical diagnosis.

From mouse models, to pluripotent stem cell lines, to pioneering the construction and use of organoids, Flora Vaccarino has been at the forefront of brain research since joining the Yale School of Medicine faculty more than 25 years ago.

Ruslan Medzhitov, PhD, is looking to conceptual models—such as systems theory, control theory, adaptation, and trade-offs—from fields like physics, economics, math, and evolutionary biology and applying them to broad questions about human health.

Damage to nerves of the brain and spinal cord is particularly devastating because these nerves do not grow back on their own. Perhaps, suggests a Yale-led study, they could regrow with a little help from science.